Aptevo Therapeutics (APVO) was advancing almost 7% Wednesday after the company said the first patient with acute myeloid leukemia dosed in a phase 1b/2 trial evaluating its mipletamig immune-oncology candidate together with standard of care venetoclax and azacitidine achieved a 90% reduction in leukemic blasts within the first 30 days of treatment.
The encouraging initial results continue the overall efficacy, safety and tolerability seen for mipletamig in prior studies, alongside evidence of durable remission, the biotechnology company said.
The open-label study is evaluating the combination of mipletamig with standard of care treatments as frontline combination therapy for leukemia in as many of 39 patients who will be treated across five dosing levels.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。